|
|
 Previous Article | Table of Contents | Next Article 
Detection of Lymphoma in Bone Marrow by Whole-Body Positron
Emission Tomography
Robert Carr,
Sally F. Barrington,
Bella Madan,
Michael J. O'Doherty, Catherine A.B. Saunders,
Jon van der Walt, and
Adrian
R. Timothy
From the Departments of Haematology, Histopathology, Clinical
Oncology and The Clinical PET Centre, United Medical and Dental Schools
of Guy's and St Thomas's, London, UK.
Positron emission tomography (PET) is a whole-body imaging technique
using 18 fluorine-fluorodeoxyglucose (FDG), whose uptake is increased
in tumor cells. Published studies have shown PET to be an effective
method of staging lymphoma and to be more sensitive than CT at
detecting extranodal disease. The purpose of this study was to
determine whether the increased marrow uptake of FDG observed in some
lymphoma patients during routine staging PET scans represented marrow
involvement by disease. PET scans of 50 patients with Hodgkin's (12)
and non-Hodgkin's (38) lymphoma were analyzed by three independent observers and the marrow graded as normal or abnormal using a visual
grading system. Unilateral iliac crest marrow aspirates and biopsies
were performed on all patients. The PET scan and marrow histology
agreed in 39 patients (78%), being concordant positive in 13 and
concordant negative in 26 patients. In 8 patients the PET scan showed
increased FDG uptake but staging biopsy was negative; in 4 of these 8 patients the PET scan showed a normal marrow background with focal FDG
"hot spots" distant from the site biopsied. In 3 patients the
marrow biopsy specimen was positive but the PET scan normal; 2 of these
3 patients had non-Hodgkin's lymphoma whose malignant cells did not
take up FDG at lymph node or marrow disease sites. Therefore, there
were only 5 patients (10%) in whom there was a difference between the
PET scan and biopsy result which could not be fully explained. Visual
interpretation of marrow FDG uptake during whole-body staging PET scans
can correctly assess marrow disease status in a high proportion of
lymphoma patients. PET has the potential to reduce the need for staging marrow biopsy.
Blood, Vol. 91 No. 9 (May 1), 1998:
pp. 3340-3346
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Noy, H. Schoder, M. Gonen, M. Weissler, K. Ertelt, C. Cohler, C. Portlock, P. Hamlin, and H. W. D. Yeung
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)
Ann. Onc.,
March 1, 2009;
20(3):
508 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood,
November 15, 2007;
110(10):
3507 - 3516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kako, K. Izutsu, Y. Ota, Y. Minatani, M. Sugaya, T. Momose, K. Ohtomo, Y. Kanda, S. Chiba, T. Motokura, et al.
FDG-PET in T-cell and NK-cell neoplasms
Ann. Onc.,
October 1, 2007;
18(10):
1685 - 1690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology,
February 1, 2007;
242(2):
360 - 385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid
Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
259 - 265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Even-Sapir
Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities
J. Nucl. Med.,
August 1, 2005;
46(8):
1356 - 1367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schoder, A. Noy, M. Gonen, L. Weng, D. Green, Y. E. Erdi, S. M. Larson, and H. W.D. Yeung
Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
July 20, 2005;
23(21):
4643 - 4651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. E. Pakos, A. D. Fotopoulos, and J. P.A. Ioannidis
18F-FDG PET for Evaluation of Bone Marrow Infiltration in Staging of Lymphoma: A Meta-Analysis
J. Nucl. Med.,
June 1, 2005;
46(6):
958 - 963.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res.,
April 15, 2005;
11(8):
2785 - 2808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. G. Schaefer, T. F. Hany, C. Taverna, B. Seifert, K. D. M. Stumpe, G. K. von Schulthess, and G. W. Goerres
Non-Hodgkin Lymphoma and Hodgkin Disease: Coregistered FDG PET and CT at Staging and Restaging--Do We Need Contrast-enhanced CT?
Radiology,
September 1, 2004;
232(3):
823 - 829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Rohren, T. G. Turkington, and R. E. Coleman
Clinical Applications of PET in Oncology
Radiology,
May 1, 2004;
231(2):
305 - 332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Meyer, R. F. Ambinder, and S. Stroobants
Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice
Hematology,
January 1, 2004;
2004(1):
184 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Friedberg and V. Chengazi
PET Scans in the Staging of Lymphoma: Current Status
Oncologist,
October 1, 2003;
8(5):
438 - 447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wagner, U. Seitz, A. Buck, B. Neumaier, S. Schultheiss, M. Bangerter, M. Bommer, F. Leithauser, E. Wawra, G. Munzert, et al.
3'-[18F]Fluoro-3'-Deoxythymidine ([18F]-FLT) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease
Cancer Res.,
May 15, 2003;
63(10):
2681 - 2687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith
Clinical Role of FDG PET in Evaluation of Cancer Patients
RadioGraphics,
March 1, 2003;
23(2):
315 - 340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M N Maisey
Overview of clinical PET
Br. J. Radiol.,
November 1, 2002;
75(90009):
S1 - 5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S F Barrington
Whole body applications of positron emission tomography in oncology
Imaging,
September 1, 2001;
13(3):
185 - 196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schoder, J. Meta, C. Yap, M. Ariannejad, J. Rao, M. E. Phelps, P. E. Valk, J. Sayre, and J. Czernin
Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma
J. Nucl. Med.,
August 1, 2001;
42(8):
1139 - 1143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps
A Tabulated Summary of the FDG PET Literature
J. Nucl. Med.,
May 1, 2001;
42(90050):
1S - 93.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Sutinen, S. Jyrkkio, M. Varpula, P. Lindholm, T. Gronroos, P. Lehikoinen, M. Teras, and H. Minn
Nodal Staging of Lymphoma with Whole-Body PET: Comparison of [11C]Methionine and FDG
J. Nucl. Med.,
December 1, 2000;
41(12):
1980 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, S. J. Horning, B. Coiffier, M. A. Shipp, R. I. Fisher, J. M. Connors, T. A. Lister, J. Vose, A. Grillo-Lopez, A. Hagenbeek, et al.
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
J. Clin. Oncol.,
April 1, 1999;
17(4):
1244 - 1244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
